Serum interleukin-6 concentration reflects the extent of asymptomatic left ventricular dysfunction and predicts progression to heart failure in patients with stable coronary artery disease

Cytokine

Volumn 54, Issue 3, 2011, Pages 266-271

  Hudzik, Bartosz ^a   Szkodzinski, Janusz ^a   Romanowski, Wojciech ^a   Danikiewicz, Aleksander ^a   Wilczek, Krzysztof ^a   Lekston, Andrzej ^a   Polonski, Lech ^a   Zubelewicz Szkodzinska, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Asymptomatic left ventricular dysfunction; Interleukin 6

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTOLIC DYSFUNCTION;

AGED; CARDIOLOGY; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK; ROC CURVE; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79955143267     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.02.012     Document Type: Article

References (27)

1. Hammermeister K.E., DeRouen T.A., Dodge H.T. Variables predictive of survival in patients with coronary disease. Selection by univariate, multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979, 59:421-430.
2. Weiner D.A., Ryan T.J., McCabe C.H., Chaitman B.R., Sheffield L.T., Ferguson J.C., et al. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol 1984, 3:772-779.
3. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995, 38(2001):2101-2113.
4. Mann D.L. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001, 6:71-80.
5. Wollert K.C., Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001, 6:95-103.
6. Munger M.A., Johnson B., Amber I.J., Callahan K.S., Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727.
7. Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998, 31:391-398.
8. MacGowan G.A., Mann D.L., Kormos R.L., Feldman A.M., Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997, 79:1128-1131.
9. Kosar F., Aksoy Y., Ozguntekin G., Ozerol I., Varol E. Relationship between cytokines, tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006, 8:270-274.
10. Raymond R.J., Dehmer G.J., Theoharides T.C., Deliargyris E.N. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 2001, 141:435-438.
11. Hudzik B., Szkodzinski J., Romanowski W., Danikiewicz A., Lekston A., Polonski L., et al. Serum interleukin-6 concentration predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Eur Cytokine Netw 2010, 21:129-135.
12. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
13. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
14. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson Developed P.A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989.
15. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992, 257:387-389.
16. + ATPase (SERCA2) in cardiac myocytes. Basic Res Cardiol 2000, 95:47-54.
17. Zimmetand J.M., Hare J.M. Nitroso-redox interactions in the cardiovascular system. Circulation 2006, 114:1531-1544.
18. Zhang H., Wang H.Y., Bassel-Duby R., Maass D.L., Johnston W.E., Horton Role J.W., et al. Role of interleukin-6 in cardiac inflammation and dysfunction after burn complicated by sepsis. Am J Physiol Heart Circ Physiol 2007, 292:H2408-H2416.
19. Hirota H., Yoshida K., Kishimoto T., Taga T. Continuous activation of Gp130, a signal-transducing receptor component for interleukin 6-related cytokines Causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995, 92:4862-4866.
20. Janssen S.P., Gayan-Ramirez G., Van den Bergh A., Herijgers P., Maes K., Verbeken E., et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005, 111:996-1005.
21. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
22. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., Mann D.L. Fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206.
23. Roig E., Orus J., Pare C., Azqueta M., Filella X., Perez-Villa F., et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 1998, 82:688-690. A688.
24. Sato Y., Takatsu Y., Kataoka K., Yamada T., Taniguchi R., Sasayama S., et al. Serial interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999, 22:811-813.
25. Ahmad S., Otaal P.S., Rai T.S., Bahl A., Saikia U.N., Manoj R.K., et al. Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy. Mol Cell Biochem 2009, 324:139-145.
26. Yan A.T., Yan R.T., Cushman M., Redheuil A., Tracy R.P., Arnett Relationship D.K., et al. Interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J 2010, 31:875-882.
27. Birner C.M., Ulucan C., Fredersdorf S., Rihm M., Lowel H., Stritzke J., et al. Head-to-head IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. Cytokine 2007, 40:89-97.